In 2020, Roy et al. [145] demonstrated that tetrahydroisoquinoline (THIQ)-mediated inhibition of CD44 sensitized HNSCC cells to cisplatin treatment. The gene discussed is CD44; the disease is head and neck squamous cell carcinoma.